Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Lendify in connection with a bond issue
Mandate

Vinge has advised Lendify in connection with a bond issue

February 07, 2018 Banking and Finance

Lendify AB (”Lendify”), a P2P-lending plattform, has issued bonds in the amount of SEK 400,000,000 on 29 January 2018 through its wholly-owned subsidiary Lendify Sweden 2 AB (publ).

The bonds have a tenor of two years and an annual interest rate of three-months Stibor + 4.5%. The bonds are backed by a portfolio of promissory notes issued by consumers in Sweden in favour of Lendify.

Together with the management of the company, Carnegie Investment Bank and DNB Markets as arrangers and their legal advisor, Vinge acted for Lendify in the structuring and documentation of the transaction.

Vinge’s team consisted of Albert Wållgren, Lionardo Ojeda and Sebastian Frisk.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024